Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14303147 | 0.89 | L3MBTL1 (0.67) | L3MBTL1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5244226 | 0.88 | L3MBTL1 (0.64) | L3MBTL1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4864670 | 0.87 | L3MBTL1 (0.77) | L3MBTL1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13910971 | 0.85 | DPP4 (0.53) | KMT2AMEN1POLBALDH1A1GAA | |
| SCHEMBL26102667 | 0.82 | LMNA (0.69) | L3MBTL1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL18192052 | 0.81 | LMNA (0.72) | L3MBTL1LMNAKMT2AMEN1POLB | |
| SCHEMBL7012242 | 0.80 | LMNA (0.67) | L3MBTL1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL31643319 | 0.80 | KMT2A (0.67) | L3MBTL1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20608072 | 0.80 | LMNA (0.64) | L3MBTL1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4506781 | 0.80 | KDM4E (0.76) | L3MBTL1LMNASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| EP-1521757-B1 | TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | REN, TACR1, AGTR1 | L3MBTL1 4262/4885LMNA 1499/4885SMN1; SMN2 3716/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | L3MBTL1 4236/4885LMNA 1862/4885SMN1; SMN2 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.